Categories & Search

Industry: Pharmaceutical

In False Ad Dispute Between Inhaler Companies, Court Grants PI Enjoining Unsupportable Clinical Superiority Claims

In its recent decision granting a preliminary injunction in GlaxoSmithKline v. Boehringer Ingelheim Pharmaceuticals, No. 19-5321, the United States District Court for the Eastern District of Pennsylvania enjoined a pharmaceutical company from making certain marketing claims of clinical superiority that the Court found did not match up with the study results purportedly supporting them. In doing so, the Court offered instructive guidance on the proof required to show falsity under the Lanham Act and on the showing necessary to justify preliminary injunctive relief.

Go

Misbranded Editors Present Webinar On “Hot Topics in Consumer False Advertising Litigation”

Last month, Misbranded co-editors Josh Kipnees, Jonah Knobler, and Jane Metcalf presented a live-streamed webinar via Bloomberg Law titled “Hot Topics in Consumer False Advertising Litigation.”  The free hour-long webinar, now available on demand, covers the following subjects, some of which should be familiar to regular readers of this blog:

  • “Natural” / “no artificial ingredients” claims

  • “No preservatives” claims

  • Ingredient claims (“made with [X]”)

  • Geographic origin claims (e.g., “Made in the USA”)

  • Slack-fill claims

  • Claims involving nondisclosure of morally troubling/offensive facts

  • What’s next in consumer false advertising litigation?

We encourage you to check it out (and obtain some CLE credit in the process).

Go